联合雄激素阻断治疗前列腺癌所致贫血的研究  

Anemia in patients on combined androgen block therapy for prostate cancer

作　　者：华立新[1] 吴宏飞[1] 眭元庚[1] 程双管[1] 徐正铨[1] 张炜[1] 

机构地区：[1]南京医科大学第一附属医院泌尿外科,210029

出　　处：《中华肿瘤杂志》2003年第5期496-497,共2页Chinese Journal of Oncology

摘　　要：目的　研究联合雄激素阻断治疗对前列腺癌患者血红蛋白 (Hb)和红细胞压积 (Ht)的影响。方法　 136例前列腺癌患者采用联合雄激素阻断治疗 (睾丸切除 +氟他胺或福至尔 ,2 5 0mg/次 ,3次 /d)。治疗前及治疗后 1,2 ,3,6 ,9和 12个月分别检测患者的Hb和Ht。 6例贫血症状严重的患者采用重组人红细胞生成素 (RHE)治疗。结果　治疗前及治疗后 1,2 ,3,6 ,9和 12个月患者的Hb分别为 :(136± 14 )g/L、(12 6± 16 )g/L、(12 1± 14 )g/L、(12 0± 15 )g/L、(113± 12 )g/L、(12 1± 13)g/L和 (12 3± 15 )g/L ;Ht分别为 :0 .4 2 4± 0 .0 4 1、0 .390± 0 .0 38、0 .381± 0 .0 4 2、0 .378± 0 .0 38、0 .36 6± 0 .0 4 1、0 .0 384± 0 .0 39和 0 .387± 0 .0 4 0。治疗后与治疗前相比 ,差异均有显著性 (P <0 .0 5 )。贫血严重者 ,RHE治疗后贫血症状改善。结论　联合雄激素阻断治疗可导致贫血 ,对此类患者要定期监测Hb及Ht。重组人促红细胞生成素可用于纠正此类贫血。Objective To study the effect of combined androgen block therapy on hemoglobin (Hb) and hematocrit value (Ht) in patients with prostate cancer. Methods One hundred and thirty-six patients with adenocarcinoma of the prostate were treated with combined androgen block(orchiectomy and flutamide 250 mg, Tid). Complete blood counts were detected before initiation and after 1, 2, 3, 6, 9 and 12 months of therapy. Results Hb level declined significantly in all patients from a mean baseline of (136±14) g/L to (126±16) g/L, (121±14) g/L, (120±15) g/L, (113±12) g/L, (121±13) g/L and (123±15) g/L at 1, 2, 3, 6, 9 and 12 months. Ht decreased from a mean baseline of 0.424±0.041 to 0.390±0.038, 0.381±0.042, 0.378±0.038, 0.366±0.041, 0.384±0.039 and 0.387±0.040. The differences between Hb, Ht before and after treatment were significant(P<0.05). Conclusion Patients with prostate cancer being treated with combined androgen block would develop a significant degree of anemia. Hemoglobin and hematocrit level should be monitored periodically. This kind of anemia can be treated by recombinant human erythropoietin.

关 键 词：雄激素 治疗 前列腺癌 贫血 研究 

分 类 号：R737.25[医药卫生—肿瘤] R556[医药卫生—临床医学]